1.275

4.41% -0.055

NanoViricides Inc (NNVC)

Overview News Price History Option Chain Discussions Forecast Stock Split

NanoViricides Inc stock is traded at $1.275, with a volume of 159.20K. It is down -4.41% in the last 24 hours and down -14.10% over the past month. NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Previous Close:

$1.33

Open:

$1.31

24h Volume:

159.20K

Relative Volume:

0.18

Market Cap:

$32.51M

Revenue:

Net Income/Loss:

$-8.09M

P/E Ratio:

-2.9283

EPS:

-0.4354

Net Cash Flow:

$-7.37M

1W Performance:

-6.52%

1M Performance:

-14.10%

6M Performance:

+22.24%

1Y Performance:

-11.72%

1-Day Range:

$1.27

$1.31

1-Week Range:

$1.27

$1.39

52-Week Range:

$0.85

$2.2299

NanoViricides Inc Stock (NNVC) Company Profile

Name

NanoViricides Inc

Sector

Healthcare (1087)

Industry

Biotechnology (604)

Phone

203-937-6137

Address

1 Controls Drive, Shelton, CT

Employee

Twitter

@nnvcnyse

Next Earnings Date

2026-10-05

Latest SEC Filings

NNVC's Discussions on Twitter

Compare NNVC vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NNVC NanoViricides Inc	1.275	33.40M	0	-8.09M	-7.37M	-0.4354
VRTX Vertex Pharmaceuticals Inc	549.37	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	826.11	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,015.37	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.30	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.59	45.38B	742.00K	-1.37B	-1.07B	-7.0731

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-25	Initiated	Alliance Global Partners	Buy
Feb-11-15	Initiated	Midtown Partners	Strong Buy

NanoViricides Inc Stock (NNVC) Latest News

Aug 21, 2026

NanoViricides (NYSE American: NNVC) sets up warrant resale, up to $4.4M cash - Stock Titan

Aug 21, 2026

Aug 20, 2026

NanoViricides (NNVC) Levels: Finishes 0.82% Down at $1.33 at the Close; Chart Watch: Traders Can Monitor the $1.26-$1.40 Range in the Current UpdateHigh Conviction Picks - vinanet.vn

Aug 20, 2026

Aug 18, 2026

NanoViricides Prepares for Phase II Ebola Trial of Oral Drug Candidate in DRC - citybuzz -

Aug 18, 2026

NNVC Q2 2026 Earnings: EPS Surprise of 22.97% Bolsters Sentiment as Shares Rise 1.47%Interim Report - vinanet.vn

Aug 14, 2026

NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Marks 22.97% Positive SurpriseQuarterly Earnings Report - vinanet.vn

Aug 14, 2026

NanoViricides (NNVC) Edges Lower to $1.36 as Antiviral Developer Holds Support ZoneNews Sentiment - vinanet.vn

Aug 14, 2026

NanoViricides (NNVC) Slips to $1.36 as Biotech Micro-Cap Tests Key Support ZoneImpulse Wave - Vinanet

Aug 14, 2026

Aug 12, 2026

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak - ACCESS Newswire

Aug 12, 2026

Aug 11, 2026

NanoViricides (NNVC) Holds Ground Near $1.40 Amid Range-Bound TradingLow Vol ETF - vinanet.vn

Aug 11, 2026

Aug 10, 2026